CUMYL-PEGACLONE explained

Iupac Name:2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-pentyl-1H-pyrido[4,3-b]indol-1-one
Width:200px
Legal Br:F2
Legal Br Comment:[1]
Legal Ca:Schedule II
Legal De:Anlage II
Legal Uk:PSA
Legal Un:P II
Legal Un Comment:[2]
Cas Number:2160555-55-3
Pubchem:134818034
Kegg:C22782
Chemspiderid:68003813
Unii:CUT2RV7EIQ
Smiles:CC(C1=CC=CC=C1)(C)N2C=CC(N(CCCCC)C3=C4C=CC=C3)=C4C2=O
C:25
H:28
N:2
O:1
Stdinchi:1S/C25H28N2O/c1-4-5-11-17-26-21-15-10-9-14-20(21)23-22(26)16-18-27(24(23)28)
Stdinchikey:AWHWTKXMUJLSRM-UHFFFAOYSA-N

CUMYL-PEGACLONE (SGT-151) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug.[3] [4] [5] [6] [7] [8] The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by Bristol-Myers Squibb in 2001.[9] [10] [11]

Legal status

Sweden's public health agency classified CUMYL-PEGACLONE as a narcotic substance, on January 18, 2019.[12]

In the United States, the DEA has temporarily placed CUMYL-PEGACLONE into Schedule I status starting on December 12th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file for permanent placement the temporary Schedule I order will expire on December 12th, 2025.[13]

See also

Notes and References

  1. Web site: Anvisa . Brazilian Health Regulatory Agency . 2023-07-24 . RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 . 2023-08-27 . 2023-08-27 . . pt-BR . 2023-07-25.
  2. Web site: Substance Details CUMYL-PEGACLONE . 2024-01-22.
  3. Ernst L, Brandhorst K, Papke U, Altrogge A, Zodel S, Langer N, Beuerle T . Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: Update of the German situation in early 2017 . Forensic Science International . 277 . 51–58 . August 2017 . 28601726 . 10.1016/j.forsciint.2017.05.019 .
  4. Angerer V, Mogler L, Steitz JP, Bisel P, Hess C, Schoeder CT, Müller CE, Huppertz LM, Westphal F, Schäper J, Auwärter V . Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE . Drug Testing and Analysis . July 2017 . 10 . 3 . 597–603 . 28670781 . 10.1002/dta.2237 .
  5. Mogler L, Wilde M, Huppertz LM, Weinfurtner G, Franz F, Auwärter V . Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples . Drug Testing and Analysis . January 2018 . 10 . 5 . 886–891 . 29314750 . 10.1002/dta.2352 .
  6. Halter S, Angerer V, Röhrich J, Groth O, Roider G, Hermanns-Clausen M, Auwärter V . Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market? . Drug Testing and Analysis . 11 . 2 . 347–349 . February 2019 . 30468574 . 10.1002/dta.2545 . 53723006 .
  7. Janssens L, Cannaert A, Connolly MJ, Liu H, Stove CP . In vitro activity profiling of Cumyl-PEGACLONE variants at the CB1 receptor: Fluorination versus isomer exploration . Drug Testing and Analysis . 12 . 9 . 1336–1343 . September 2020 . 32490586 . 10.1002/dta.2870 . 1854/LU-8687072 . 219285656 . free .
  8. Tiemensma M, Rutherford JD, Scott T, Karch S . Emergence of Cumyl-PEGACLONE-related fatalities in the Northern Territory of Australia . Forensic Science, Medicine, and Pathology . 17. 1. 3–9. November 2020 . 33185835 . 10.1007/s12024-020-00334-0 . 226309264 .
  9. WO . 2001058869 . application . Cannabinoid Receptor Modulators, Their Processes of Preparation, and Use of Cannabinoid Receptor Modulators in Treating Respiratory and Non-Respiratory Diseases . 16 August 2001 . 11 February 2000 . Leftheris K, Zhao, R, Chen BC, Kiener P, Wu H, Pandit C, Chennagiri R, Wrobleski S, Chen P, Hynes j, Longphre M, Norris D, Spergel S, Tokarski J . Bristol-Myers Squibb Company .
  10. Wrobleski ST, Chen P, Hynes J, Lin S, Norris DJ, Pandit CR, Spergel S, Wu H, Tokarski JS, Chen X, Gillooly KM, Kiener PA, McIntyre KW, Patil-Koota V, Shuster DJ, Turk LA, Yang G, Leftheris K . Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties . Journal of Medicinal Chemistry . 46 . 11 . 2110–6 . May 2003 . 12747783 . 10.1021/jm020329q .
  11. Alam RM, Keating JJ . Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists . Drug Testing and Analysis . 12 . 3 . 297–315 . March 2020 . 31854124 . 10.1002/dta.2752 . 209417068 .
  12. Web site: Sexton nya ämnen klassas som narkotika eller hälsofarlig vara . Folkhälsomyndigheten . sv . 18 January 2019 . 11 November 2019 . 3 June 2021 . https://web.archive.org/web/20210603114630/https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/januari/sexton-nya-amnen-klassas-som-narkotika-eller-halsofarlig-vara/ . dead .
  13. Web site: Federal Register :: Request Access .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CUMYL-PEGACLONE".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.